Your browser does not fully support modern features. Please upgrade for a smoother experience.
Submitted Successfully!
Thank you for your contribution! You can also upload a video entry or images related to this topic. For video creation, please contact our Academic Video Service.
Version Summary Created by Modification Content Size Created at Operation
1 Raefa Abou Khouzam -- 1253 2023-03-09 17:19:09 |
2 format correct Conner Chen Meta information modification 1253 2023-03-13 06:18:26 |

Video Upload Options

We provide professional Academic Video Service to translate complex research into visually appealing presentations. Would you like to try it?
No, upload directly Yes
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Abou Khouzam, R.; Lehn, J.; Mayr, H.; Clavien, P.; Wallace, M.B.; Ducreux, M.; Limani, P.; Chouaib, S. Role of Hypoxia in Pancreatic Ductal Adenocarcinoma Carcinogenesis. Encyclopedia. Available online: https://encyclopedia.pub/entry/42036 (accessed on 13 January 2026).
Abou Khouzam R, Lehn J, Mayr H, Clavien P, Wallace MB, Ducreux M, et al. Role of Hypoxia in Pancreatic Ductal Adenocarcinoma Carcinogenesis. Encyclopedia. Available at: https://encyclopedia.pub/entry/42036. Accessed January 13, 2026.
Abou Khouzam, Raefa, Jean-Marie Lehn, Hemma Mayr, Pierre-Alain Clavien, Michael Bradley Wallace, Michel Ducreux, Perparim Limani, Salem Chouaib. "Role of Hypoxia in Pancreatic Ductal Adenocarcinoma Carcinogenesis" Encyclopedia, https://encyclopedia.pub/entry/42036 (accessed January 13, 2026).
Abou Khouzam, R., Lehn, J., Mayr, H., Clavien, P., Wallace, M.B., Ducreux, M., Limani, P., & Chouaib, S. (2023, March 09). Role of Hypoxia in Pancreatic Ductal Adenocarcinoma Carcinogenesis. In Encyclopedia. https://encyclopedia.pub/entry/42036
Abou Khouzam, Raefa, et al. "Role of Hypoxia in Pancreatic Ductal Adenocarcinoma Carcinogenesis." Encyclopedia. Web. 09 March, 2023.
Role of Hypoxia in Pancreatic Ductal Adenocarcinoma Carcinogenesis
Edit
This entry is adapted from the peer-reviewed paper 10.3390/cancers15041235

Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer, and it is a disease of dismal prognosis. While immunotherapy has revolutionized the treatment of various solid tumors, it has achieved little success in PDAC. Hypoxia within the stroma-rich tumor microenvironment is associated with resistance to therapies and promotes angiogenesis, giving rise to a chaotic and leaky vasculature that is inefficient at shuttling oxygen and nutrients. Hypoxia and its downstream effectors have been implicated in immune resistance and could be contributing to the lack of response to immunotherapy experienced by patients with PDAC.

hypoxia pancreatic cancer immunotherapy hypoxia signature genomic instability vascular normalization

1. Introduction

Most pancreatic tumors (around 95%) manifest from the exocrine parenchyma of the gland, arising from connective tissue, acinar cells, or the ductal epithelium [1]. Pancreatic duct adenocarcinoma (PDAC) is the most common, accounting for more than 80% of pancreatic cancer cases [1][2]. Pancreatic cancer is associated with poor survival and the incident cases and number of deaths have reportedly doubled from 1990 to 2017 [3] and remain on a trending increase [4]. New treatment strategies are clearly necessary to enhance patient outcomes.
Immunotherapy, and in particular immune checkpoint inhibitors (ICIs), enable the activation of T cells to clear tumor cells. This is mainly by blocking inhibitory signals arising from the interaction between programmed death receptor 1 (PD1) and the cytotoxic T lymphocyte-associated protein 4 (CTLA4) with their ligands, programmed death ligand 1 (PD-L1) and B7 ligands, respectively [5]. ICIs have significantly enhanced the survival of treatment-refractory patients with metastatic melanoma [6] and non-small cell lung cancer [7], but have thus far yielded dismal responses in pancreatic cancer, even when applied in combination with chemotherapy [5][8]. The only patient subset with acceptable responses is those having microsatellite instability (MSI) or deficient mismatch repair (dMMR); in addition, high tumor mutational burden (TMB) has been significantly associated with improved overall survival after ICI treatment [9]. In patients suffering from PDAC, however, only 1–2% are mismatch repair deficient and most cases present with low TMB (<10 mutations/megabase) [10][11]. Other biomarkers of response, namely PD-L1 expression and infiltrating CD8+ T cells, have not had an established role in selecting patients with PDAC for ICI therapy [5]. An improved understanding of tumor evolution and the PDAC tumor microenvironment (TME) is necessary to bring forth more pertinent makers of responses in this disease and better combination treatments.

2. Role of Hypoxia in PDAC Carcinogenesis

Findings from various studies have been recently combined to propose an updated evolutionary model for PDAC, where often a simple KRAS-activating mutation transforms a ductal epithelial cell, contributing to low-grade pancreatic intraepithelial neoplasia (PanIN). Subsequent incursion of loss of tumor suppressors involved in the cell cycle control, namely TP53, CDKN2A and/or SMAD4, promote cell growth and the progression of the lesion to high-grade PanIN. An unknown trigger, which could be telomere loss, promotes complex mitotic errors manifesting as polyploidy in most cases, and chromothripsis in others, enables faster acquisition of structural alterations and copy number variations (CNVs). The result is rapid proliferation, heterogenous driver and pathway alterations, a compendium of transcriptional subtypes, KRAS allelic imbalance, invasion, and dissemination [12]. On the other hand, in KRAS wildtype (WT) PDACs, which represent 10.7% of cases, a recent report determined that TP53 is the most frequently mutated gene closely followed by BRAF [13], while gene amplification and fusion events occur in 10% and 21% of KRAS WT cases, respectively [13]. In addition, a small fraction of PDACs present with single base substitution (SBS) signatures of homologous recombination deficiency (HRD) (10%) or dMMR-related signatures (1–2%). HRD and dMMR are primarily due to germline alterations in BRCA1, BRCA2, PALB2 or RAD51C involved in the homologous recombination repair (HRR) pathway, or MLH1, MSH2, MSH6 or PMS2 involved in MMR. Germline alterations are followed by a second somatic mutation, leading to biallelic inactivation [14][15][16]. CNVs and structural variants have also been surveyed in PDAC genomes distributing them into four subtypes. This included an “unstable” subtype, which harbors greater than 200 variants [17], and was found to be associated with the HRD signature. Of interest, a recent study correlated readouts from transcriptome-based hypoxia gene signatures across tumor types with copy number signature attributes. The authors reported a significant positive correlation between hypoxia as determined by these signatures, and attributes related to HRD and aneuploidy [18]. Indeed, hypoxia has been associated with the increase in genomic instability and TMB [19][20][21][22][23][24]. In that respect, hypoxia could potentially increase neoantigen load, thus giving rise to the emergence of cancer clones that could potentially be recognized as non-self and be eliminated by the immune response. For that to be achieved however, anti-tumor immune cells need to be within the tumor mass, which is a rare scenario in PDACs that are branded as being immune-cold tumors characterized by a highly desmoplastic, hypovascularized, and hypoxic TME [25][26].
The adaptive response to hypoxia confers PDAC malignancy by promoting more aggressive and treatment-refractory phenotypes [26]. The primary activator of the hypoxia-mediated response is the hypoxia-inducible factor-1α (HIF-1α). The stability of this transcription factor is determined by the presence of oxygen since the protein responsible for initiating its degradation, prolyl hydroxylase (PHD), is activated in an oxygen-dependent manner. In the TME, the drop in oxygen levels associated with hypoxia will stabilize HIF-1α, enabling its translocation to the nucleus where it interacts with the HIF-1β subunit giving rise to a transcriptionally active heterodimer that induces the expression of more than a hundred genes. This is achieved by engaging the hypoxia response elements (HRE) in their promotor regions. Among the activated genes are those necessary for sustaining energy production in the cells, which mainly occurs via the activation of glycolysis, inhibition of oxidative phosphorylation, and by increasing the expression of glucose transporters to enable the higher uptake of this nutrient [27]. The increased intracellular acidity resulting from the hypoxia-promoted metabolic switch is counteracted though the HIF-1α induction of factors responsible for shuttling the excess lactate and hydrogen ions outside the cell. The cumulative effect is a nutrient-deprived and highly acidic TME that is hostile to the function of tumor-antagonizing cells such as cytotoxic T-cells, while being highly favorable to regulatory T cells (Tregs) and M2-polarized macrophages, which support tumor growth [28]. In addition, the leaky, haphazardly structured, and disorganized blood vessels that are instigated by hypoxia act as a physical barrier to the recruitment of immune cells [29]. A second canonical inducible activator of the response to hypoxia is the HIF-1α homologue, HIF-2α [30][31]. While there is an overlap between the responses triggered by HIFs, each isoform has a specific set of target genes [30][31]. With respect to pancreatic cancer, there have been controversial reports on the involvement of HIF-2α; however, the regulation of β-catenin by HIF-2α was found to be critical for the formation of early pancreatic lesions [32]. A more in-depth study further confirmed the crosstalk between HIF-2α and Wnt/β-catenin signaling by showing that the interaction between the two proteins increased the activity of β-catenin, while enhancing the stability of HIF-2α [33]. Furthermore, HIF-2α was shown to promote pancreatic tumor cell proliferation, metabolic shift and stemness features. It was also correlated with markers of epithelial-to-mesenchymal transition (EMT) in vivo; and with a worse prognosis in patients with pancreatic cancer [32]. In a more recent study in PDAC mouse models, HIF-2α expression in cancer-associated fibroblasts (CAFs) was found to play a key role in tumor progression and growth, as well as the recruitment of immunosuppressive immune cells to the TME [34]. Interestingly, treating PDAC mice with a HIF-2α inhibitor reduced immunosuppression and enhanced the response to immunotherapy [34]. Similar findings have been reported when combining other hypoxia-targeted approaches with ICIs, as discussed later. Indeed, relieving hypoxia could transform immune-cold tumors to immune-hot and potentiate responses to immunotherapy.

References

  1. Ducreux, M.; Cuhna, A.S.; Caramella, C.; Hollebecque, A.; Burtin, P.; Goéré, D.; Seufferlein, T.; Haustermans, K.; Van Laethem, J.L.; Conroy, T.; et al. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2015, 26 (Suppl. S5), v56–v68.
  2. Christenson, E.S.; Jaffee, E.; Azad, N.S. Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: A bright future. Lancet Oncol. 2020, 21, e135–e145.
  3. Collaborators GPC. The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol. Hepatol. 2019, 4, 934–947.
  4. Huang, J.; Lok, V.; Ngai, C.H.; Zhang, L.; Yuan, J.; Lao, X.Q.; Ng, K.; Chong, C.; Zheng, Z.-J.; Wong, M.C. Worldwide Burden of, Risk Factors for, and Trends in Pancreatic Cancer. Gastroenterology 2021, 160, 744–754.
  5. Bockorny, B.; Grossman, J.E.; Hidalgo, M. Facts and Hopes in Immunotherapy of Pancreatic Cancer. Clin. Cancer Res. 2022, 28, 4606–4617.
  6. Larkin, J.; Chiarion-Sileni, V.; Gonzalez, R.; Grob, J.-J.; Rutkowski, P.; Lao, C.D.; Cowey, C.L.; Schadendorf, D.; Wagstaff, J.; Dummer, R.; et al. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N. Engl. J. Med. 2019, 381, 1535–1546.
  7. Gandhi, L.; Rodríguez-Abreu, D.; Gadgeel, S.; Esteban, E.; Felip, E.; De Angelis, F.; Domine, M.; Clingan, P.; Hochmair, M.J.; Powell, S.F.; et al. Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer. N. Engl. J. Med. 2018, 378, 2078–2092.
  8. Padrón, L.J.; Maurer, D.M.; O’Hara, M.H.; O’Reilly, E.M.; Wolff, R.A.; Wainberg, Z.A.; Ko, A.H.; Fisher, G.; Rahma, O.; Lyman, J.P.; et al. Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: Clinical and immunologic analyses from the randomized phase 2 PRINCE trial. Nat. Med. 2022, 28, 1167–1177.
  9. Samstein, R.M.; Lee, C.-H.; Shoushtari, A.N.; Hellmann, M.D.; Shen, R.; Janjigian, Y.Y.; Barron, D.A.; Zehir, A.; Jordan, E.J.; Omuro, A.; et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat. Genet. 2019, 51, 202–206.
  10. Hu, Z.I.; Shia, J.; Stadler, Z.K.; Varghese, A.M.; Capanu, M.; Salo-Mullen, E.; Lowery, M.A.; Diaz, L.A.; Mandelker, D.; Yu, K.H.; et al. Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations. Clin. Cancer Res. 2018, 24, 1326–1336.
  11. Luchini, C.; Brosens, L.A.A.; Wood, L.D.; Chatterjee, D.; Shin, J.I.; Sciammarella, C.; Fiadone, G.; Malleo, G.; Salvia, R.; Kryklyva, V.; et al. Comprehensive characterisation of pancreatic ductal adenocarcinoma with microsatellite instability: Histology, molecular pathology and clinical implications. Gut 2021, 70, 148–156.
  12. Connor, A.A.; Gallinger, S. Pancreatic cancer evolution and heterogeneity: Integrating omics and clinical data. Nat. Rev. Cancer 2022, 22, 131–142.
  13. Philip, P.A.; Azar, I.; Xiu, J.; Hall, M.J.; Hendifar, A.E.; Lou, E.; Hwang, J.J.; Gong, J.; Feldman, R.; Ellis, M.; et al. Molecular Characterization of KRAS Wild-type Tumors in Patients with Pancreatic Adenocarcinoma. Clin. Cancer Res. 2022, 28, 2704–2714.
  14. Connor, A.A.; Denroche, R.E.; Jang, G.H.; Timms, L.; Kalimuthu, S.N.; Selander, I.; McPherson, T.; Wilson, G.W.; Chan-Seng-Yue, M.; Borozan, I.; et al. Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma. JAMA Oncol. 2017, 3, 774–783.
  15. Fraune, C.; Burandt, E.; Simon, R.; Hube-Magg, C.; Makrypidi-Fraune, G.; Kluth, M.; Büscheck, F.; Höflmayer, D.; Blessin, N.C.; Mandelkow, T.; et al. MMR Deficiency is Homogeneous in Pancreatic Carcinoma and Associated with High Density of Cd8-Positive Lymphocytes. Ann. Surg. Oncol. 2020, 27, 3997–4006.
  16. Golan, T.; O’Kane, G.M.; Denroche, R.E.; Raitses-Gurevich, M.; Grant, R.C.; Holter, S.; Wang, Y.; Zhang, A.; Jang, G.H.; Stossel, C.; et al. Genomic Features and Classification of Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma. Gastroenterology 2021, 160, 2119–2132.
  17. Waddell, N.; Pajic, M.; Patch, A.-M.; Chang, D.K.; Kassahn, K.S.; Bailey, P.; Johns, A.L.; Miller, D.; Nones, K.; Quek, K.; et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 2015, 518, 495–501.
  18. Steele, C.D.; Abbasi, A.; Islam, S.M.A.; Bowes, A.L.; Khandekar, A.; Haase, K.; Hames-Fathi, S.; Ajayi, D.; Verfaillie, A.; Dhami, P.; et al. Signatures of copy number alterations in human cancer. Nature 2022, 606, 984–991.
  19. Hassan Venkatesh, G.; Abou Khouzam, R.; Shaaban Moustafa Elsayed, W.; Ahmed Zeinelabdin, N.; Terry, S.; Chouaib, S. Hypoxia increases mutational load of breast cancer cells through frameshift mutations. Oncoimmunology 2020, 9, 1750750.
  20. Hassan Venkatesh, G.; Abou Khouzam, R.; Shaaban Moustafa Elsayed, W.; Ahmed Zeinelabdin, N.; Terry, S.; Chouaib, S. Tumor hypoxia: An important regulator of tumor progression or a potential modulator of tumor immunogenicity? Oncoimmunology 2021, 10, 1974233.
  21. Bhandari, V.; Hoey, C.; Liu, L.Y.; Lalonde, E.; Ray, J.; Livingstone, J.; Lesurf, R.; Shiah, Y.-J.; Vujcic, T.; Huang, X.; et al. Molecular landmarks of tumor hypoxia across cancer types. Nat. Genet. 2019, 51, 308–318.
  22. Bhandari, V.; Li, C.H.; Bristow, R.G.; Boutros, P.C.; Aaltonen, L.A.; Abascal, F.; Abeshouse, A.; Aburatani, H.; Adams, D.J.; Agrawal, N.; et al. Divergent mutational processes distinguish hypoxic and normoxic tumours. Nat. Commun. 2020, 11, 737.
  23. Abou Khouzam, R.; Rao, S.P.; Venkatesh, G.H.; Zeinelabdin, N.A.; Buart, S.; Meylan, M.; Chouaib, S. An Eight-Gene Hypoxia Signature Predicts Survival in Pancreatic Cancer and Is Associated with an Immunosuppressed Tumor Microenvironment. Front. Immunol. 2021, 12, 680435.
  24. Zhuang, H.; Wang, S.; Chen, B.; Zhang, Z.; Ma, Z.; Li, Z.; Liu, C.; Zhou, Z.; Gong, Y.; Huang, S.; et al. Prognostic Stratification Based on HIF-1 Signaling for Evaluating Hypoxic Status and Immune Infiltration in Pancreatic Ductal Adenocarcinomas. Front. Immunol. 2021, 12, 790661.
  25. Erkan, M.; Kurtoglu, M.; Kleeff, J. The role of hypoxia in pancreatic cancer: A potential therapeutic target? Expert. Rev. Gastroenterol. Hepatol. 2016, 10, 301–316.
  26. Tao, J.; Yang, G.; Zhou, W.; Qiu, J.; Chen, G.; Luo, W.; Zhao, F.; You, L.; Zheng, L.; Zhang, T.; et al. Targeting hypoxic tumor microenvironment in pancreatic cancer. J. Hematol. Oncol. 2021, 14, 14.
  27. Samanta, D.; Semenza, G.L. Metabolic adaptation of cancer and immune cells mediated by hypoxia-inducible factors. Biochim. Biophys. Acta (BBA)—Rev. Cancer 2018, 1870, 15–22.
  28. Daniel, S.K.; Sullivan, K.M.; Labadie, K.P.; Pillarisetty, V.G. Hypoxia as a barrier to immunotherapy in pancreatic adenocarcinoma. Clin. Transl. Med. 2019, 8, 10.
  29. Abou Khouzam, R.; Brodaczewska, K.; Filipiak, A.; Zeinelabdin, N.A.; Buart, S.; Szczylik, C.; Chouaib, S. Tumor Hypoxia Regulates Immune Escape/Invasion: Influence on Angiogenesis and Potential Impact of Hypoxic Biomarkers on Cancer Therapies. Front. Immunol. 2020, 11, 613114.
  30. Keith, B.; Johnson, R.S.; Simon, M.C. HIF1α and HIF2α: Sibling rivalry in hypoxic tumour growth and progression. Nat. Rev. Cancer 2011, 12, 9–22.
  31. Toledo, R.A.; Jimenez, C.; Armaiz-Pena, G.; Arenillas, C.; Capdevila, J.; Dahia, P.L.M. Hypoxia-Inducible Factor 2 Alpha (HIF2α) Inhibitors: Targeting Genetically Driven Tumor Hypoxia. Endocr. Rev. 2022, bnac025.
  32. Zhang, Q.; Lou, Y.; Zhang, J.; Fu, Q.; Wei, T.; Sun, X.; Liang, T. Hypoxia-inducible factor-2alpha promotes tumor progression and has crosstalk with Wnt/beta-catenin signaling in pancreatic cancer. Mol. Cancer 2017, 16, 119.
  33. Criscimanna, A.; Duan, L.J.; Rhodes, J.A.; Fendrich, V.; Wickline, E.; Hartman, D.J.; Esni, F. PanIN-specific regulation of Wnt signaling by HIF2alpha during early pancreatic tumorigenesis. Cancer Res. 2013, 73, 4781–4790.
  34. Garcia, C.J.G.; Huang, Y.; Fuentes, N.R.; Turner, M.C.; Monberg, M.E.; Lin, D.; Taniguchi, C.M. Stromal HIF2 Regulates Immune Suppression in the Pancreatic Cancer Microenvironment. Gastroenterology 2022, 162, 2018–2031.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Biology
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register : Raefa Abou Khouzam ,
Jean-Marie Lehn
,
Hemma Mayr
, Pierre-Alain Clavien , Michael Bradley Wallace ,
Michel Ducreux
, Perparim Limani , Salem Chouaib
View Times: 537
Revisions: 2 times (View History)
Update Date: 13 Mar 2023
Table of Contents
    Notice
    You are not a member of the advisory board for this topic. If you want to update advisory board member profile, please contact office@encyclopedia.pub.
    OK
    Confirm
    Only members of the Encyclopedia advisory board for this topic are allowed to note entries. Would you like to become an advisory board member of the Encyclopedia?
    Yes
    No
    ${ textCharacter }/${ maxCharacter }
    Submit
    Cancel
    There is no comment~
    ${ textCharacter }/${ maxCharacter }
    Submit
    Cancel
    ${ selectedItem.replyTextCharacter }/${ selectedItem.replyMaxCharacter }
    Submit
    Cancel
    Confirm
    Are you sure to Delete?
    Yes No
    Academic Video Service
    Feedback